Emcure Pharmaceuticals has officially appointed Mr. C S Muralidharan as an Independent Director. Following a successful remote e-voting process conducted via postal ballot, shareholders have approved his appointment for a first term of three consecutive years. The appointment is effective as of April 1, 2026. This development strengthens the company’s board leadership and governance structure as it continues its operational growth.
Board Appointment Details
Emcure Pharmaceuticals has confirmed the formal induction of Mr. C S Muralidharan to its Board of Directors. As an Independent Director, Mr. Muralidharan brings his expertise to the company’s governance framework for a tenure of three years. His appointment is part of the company’s ongoing commitment to maintaining high standards of oversight and professional leadership.
Shareholder Approval Process
The appointment was finalized through a remote e-voting process, which concluded on April 24, 2026. Following the review of the scrutineer’s report on April 27, 2026, the company announced the successful passage of the resolution. Mr. Muralidharan, who holds the Director Identification Number 00014740, is confirmed to have no prior associations with the company’s existing Directors or Key Managerial Personnel, ensuring his status remains independent.
Source: BSE
